Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Capricor Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The source filing: Capricor Therapeutics’s 10-Q, filed May 13, 2026. Open the filing →
- Filed
- May 13, 2026, 5:20 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-060382
FAQ
- What is Capricor Therapeutics's D&A?
- Capricor Therapeutics (CAPR) reported D&A of $534.67K in Q1 2026.
- How has Capricor Therapeutics's D&A changed year-over-year?
- Capricor Therapeutics's D&A increased by 31.9% year-over-year, from $405.45K to $534.67K.
- What is the long-term trend for Capricor Therapeutics's D&A?
- Over 4 years (2021 to 2025), Capricor Therapeutics's D&A has grown at a 66.5% compound annual growth rate (CAGR), from $245.7K to $1.89M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Capricor Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude